Short answer
Spyre Therapeutics, Inc. (SYRE) filed an 8-K current report with the SEC on June 1, 2026 reporting Item 8.01 (Other Events). SPY003 license expanded beyond inflammatory bowel disease to all therapeutic, prophylactic, palliative and diagnostic uses.
Spyre Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- SPY003 license expanded beyond inflammatory bowel disease to all therapeutic, prophylactic, palliative and diagnostic uses
- Combination-trial dosing outside inflammatory bowel disease restricted until June 1, 2028
- Monotherapy dosing outside inflammatory bowel disease restricted until June 1, 2030
- Material transaction could accelerate restriction expiration to June 1, 2028, increasing strategic optionality
- Expanded rights broaden SPY003 development and partnering potential beyond the current lead indication
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Spyre Therapeutics, Inc. 8-K filings
Get the next SYRE 8-K as it lands
Follow SYRE for push alerts, or ask the research agent what this filing means.